Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound.
With the advent of non-fluorinated double esters the spectrum of topical dermatotherapy with glucocorticoids seems to have broadened to include safer congeners. To assess the atrophogenicity potential of glucocorticoids, high-frequency ultrasound has been proposed. In a comparative trial using the DUB 20 system, 24 healthy volunteers applied hydrocortisone aceponate, the corresponding vehicle, prednicarbate ointment and betamethasone-17-valerate ointment over a period of 6 weeks. While both hydrocortisone aceponate and prednicarbate ointment induced no significant reduction in skin thickness, the onset of epidermal-dermal thinning with betamethasone-17-valerate was early and the extent marked. These findings imply an increased therapeutic index with the non-fluorinated double esters.
Kerscher
M J
MJ
Department of Dermatology, Ludwig-Maximilians-Universität, München, Germany.
Korting
H C
HC
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001284:Atrophy / Q000000981:diagnostic imaging; D001624:Betamethasone Valerate / Q000008:administration & dosage / Q000494:pharmacology; D004311:Double-Blind Method; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D009824:Ointments; D011239:Prednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D012867:Skin / Q000000981:diagnostic imaging / Q000187:drug effects*; D014463:Ultrasonography
D000893:Anti-Inflammatory Agents; D009824:Ointments; C063919:hydrocortisone aceponate; D001624:Betamethasone Valerate; D011239:Prednisolone; C035287:prednicarbate; D006854:Hydrocortisone